MedTrace Logo

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

NCT00255476 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2009-04-23

No results posted yet for this study

Summary

The purpose of this study is to compare the objectie tumour response rate between the cisplatin/5FU and cisplatin/5FU plus ZD1839 combination

Conditions

  • Squamous Cell Cancer
  • Cancer of Head and Neck

Interventions

DRUG

gefitinib

DRUG

cisplatin

DRUG

5-flourouracil

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Iressa Medical Sciences Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Completion
2007-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00255476 on ClinicalTrials.gov